Comparative Pharmacology
Head-to-head clinical analysis: DYAZIDE versus HYDRO RIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYAZIDE versus HYDRO RIDE.
DYAZIDE vs HYDRO-RIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dyazide is a combination of hydrochlorothiazide, a thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal convoluted tubule, reducing sodium and water reabsorption; and triamterene, a potassium-sparing diuretic that blocks epithelial sodium channels in the collecting duct, reducing potassium excretion.
Thiazide diuretic that inhibits sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water.
1-2 capsules orally once daily; each capsule contains hydrochlorothiazide 25 mg and triamterene 50 mg.
Initiate at 12.5-25 mg orally once daily. Titrate to 50-100 mg once daily. Maximum 200 mg per day.
None Documented
None Documented
Triamterene: 1.5–2.5 hours; hydrochlorothiazide: 6–15 hours. Clinical dosing typically once daily.
Terminal half-life 4-6 hours (prolonged in renal impairment).
Renal: triamterene ~80% (as metabolites and parent), hydrochlorothiazide >95% unchanged.
Primarily renal (50% unchanged; remainder as glucuronide conjugate); biliary/fecal <10%.
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic